May 11, 2022:

Seven Big Ten Cancer Research Consortium (Big Ten CRC) abstracts will be highlighted during the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting held in Chicago, IL.

Additionally, Big Ten CRC investigators in our gastrointestinal, thoracic, breast cancer, genitourinary, head & neck, basket trial, correlative science, gynecologic and sarcoma clinical trial working groups will meet in-person during the 2022 ASCO Annual Meeting. Junior and senior faculty, fellows, bench scientists, data scientists, and others interested in collaborative oncology research within the Big Ten CRC are encouraged to attend.

Poster Discussion

BTCRC-LUN16-081: Consolidation Nivolumab plus Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III Non-small-cell Lung Cancer: BTCRC LUN 16-081

Authors include: Greg Andrew Durm, Hirva Mamdani, Sandra K. Althouse, Salma K. Jabbour, Apar Kishor Ganti, Shadia Ibrahim Jalal, Jason Alan Chesney, Jarushka Naidoo, Borys Hrinczenko, Mary Jo J. Fidler, Ticiana Leal, Lawrence Eric Feldman, Naomi Fujioka, Nasser H. Hanna.

Participating institutions: University of Illinois Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Michigan State University Cancer Research, Masonic Cancer Center, University of Minnesota, Penn State Cancer Institute, Rutgers Cancer Institute of New Jersey, Fred & Pamela Buffett Cancer Center, University of Wisconsin Carbone Cancer Center, Barbara Ann Karmanos Cancer Center, Rush University Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and University of Louisville James Graham Brown Cancer Center. 

Publication

BTCRC-BRE15-016: Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.

Participating institutions: Michigan State University, Penn State Cancer Institute, University of Illinois Cancer Center, University of Minnesota, University of Nebraska Medical Center, University of Wisconsin.

Authors include: Ziwei Zhang, Xiuyuan Ma, Julia Ekiert, Yael Simons, Louis Coleman, Cristina I. Truica, Anne Hudson Blaes, Jatin Rana, PAVANKUMAR TANDRA, Lauren Green, Menggang Yu, Deborah Toppmeyer, Ruth O’Regan, Kari Braun Wisinski, Oana Cristina Danciu, Gayatry Mohapatra, Kent Hoskins, Yu Gao

BTCRC-HN17-111: A Phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR).

Authors include: Manish Patel, Naomi Fujioka, Daniel Fellows Pease, Lawrence Eric Feldman, Francis P. Worden, Douglas Earl Laux, Yanis Boumber, Ranee Mehra, Emilian Racila, Qing Cao, Justine Yang Yang Bruce

Participating institutions: University of Illinois Cancer Center, Holden Comprehensive Cancer Center, University of Iowa, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Michigan Rogel Cancer Center, Masonic Cancer Center, University of Minnesota, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and University of Wisconsin Carbone Cancer Center. 

BTCRC-BRE18-337, Phase 2 trial with safety-run in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer.

Authors include: Sneha Deepak Phadke, Menggang Yu, Kathy Miller, Ami N. Shah, Oana Cristina Danciu, Kari Braun Wisinski

Participating institutions: University of Illinois Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Holden Comprehensive Cancer Center, University of Iowa, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and University of Wisconsin Carbone Cancer Center.

BTCRC-LUN16-081: Analysis of circulating tumor DNA in the phase 2 BTCRC LUN16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non-small cell lung cancer.

Authors include: Soyeong Jun, Nikhil Shukla, Greg Andrew Durm, Angela B. Hui, Sha Cao, Christian Kunder, Ash A. Alizadeh, Nasser H. Hanna, Maximilian Diehn

Participating institutions: University of Illinois Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Michigan State University Cancer Research, Masonic Cancer Center, University of Minnesota, Penn State Cancer Institute, Rutgers Cancer Institute of New Jersey, Fred & Pamela Buffett Cancer Center, University of Wisconsin Carbone Cancer Center, Barbara Ann Karmanos Cancer Center, Rush University Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and University of Louisville James Graham Brown Cancer Center. 

Trials in Progress

BTCRC-LUN19-396: Assessing the predictive value of ctDNA on relapse in patients with tesected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant Atezolizumab followed by Atezolizumab: BTCRC-LUN19-396.

Participating institutions: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Ohio State University Comprehensive Cancer Center, Penn State Cancer Institute, Rutgers Cancer Institute of New Jersey, University of Wisconsin and New York University Clinical Cancer Center.

Authors include: Fatemeh Ardeshir-Larijani, Nisha Anjali Mohindra, Anne M. Traynor, Jyoti Malhotra, Elaine Shum, Patrick C. Ma, Nasser H. Hanna

BTCRC-BRE19-409: A phase II, Single Arm Study of Alpelisib ( BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer. A Big Ten Cancer Research Consortium Study BTCRC –BRE-19-409.

Participating institutions: Penn State Cancer Institute, University of Illinois Cancer Center, and University of Wisconsin.

Authors include: Cristina I. Truica, Amanda Marie Parkes, Oana Cristina Danciu, Monali K. Vasekar, Kent Hoskins, Kari Braun Wisinski

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org